Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 14/20 | 0.62 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.60 |
| ▸ | INCENP | Q9NQS7 | 3/20 | 0.60 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.55 |
| ▸ | HTR1A | P08908 | 2/20 | 0.55 |
| ▸ | DRD2 | P14416 | 2/20 | 0.55 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.51 |
| ▸ | GCK | P35557 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2760114 | 0.83 | SYK (0.61) | SYKAURKBINCENP | |
| SCHEMBL12301168 | 0.82 | CA12 (0.47) | SYK | |
| SCHEMBL2250667 | 0.82 | SYK (0.52) | SYKAURKBINCENPABCB1HTR1A | |
| SCHEMBL10562958 | 0.81 | SCN8A (0.59) | SYKAURKBINCENPABCB1HTR1A | |
| SCHEMBL8625407 | 0.80 | SYK (0.55) | SYKAURKBINCENPABCB1HTR1A | |
| SCHEMBL8625403 | 0.80 | SYK (0.51) | SYKAURKBINCENPABCB1HTR1A | |
| SCHEMBL1406446 | 0.80 | SYK (0.65) | SYKAURKBINCENPABCB1HTR1A | |
| SCHEMBL6190711 | 0.80 | SYK (0.69) | SYKAURKBINCENPABCB1HTR1A | |
| SCHEMBL28762074 | 0.80 | SYK (0.56) | SYKAURKBINCENPABCB1HTR1A | |
| SCHEMBL15701533 | 0.79 | MRGPRX4 (0.52) | SYKAURKBINCENP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3611164-A1 | PYRIDONE COMPOUND, AND AGRICULTURAL AND HORTICULTURAL FUNGICIDE HAVING THIS AS ACTIVE COMPONENT | Mitsui Chemicals Agro, Inc. (JP) | 2020-02-19 | — | — | EP | disclosed |
| US-8022072-B2 | Azolylmethylidenehydrazine derivative and use thereof | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-20 | — | — | US | disclosed |
| US-8022072-B2 | Azolylmethylidenehydrazine derivative and use thereof | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-20 | — | — | US | disclosed |
| US-7795289-B2 | Use of acylaminothiazole derivatives as therapeutic agents | SANOFI-AVENTIS (FR) | 2010-09-14 | — | — | US | disclosed |
| US-7795289-B2 | Use of acylaminothiazole derivatives as therapeutic agents | SANOFI-AVENTIS (FR) | 2010-09-14 | — | — | US | disclosed |
| US-20100190754-A1 | AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100190754-A1 | AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| EP-2168951-A1 | AZOLYLMETHYLENEHYDRAZINE DERIVATIVE AND USE THEREOF | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-31 | — | — | EP | disclosed |
| US-20080051436-A1 | Use of Acylaminothiazole Derivatives as Therapeutic Agents | SANOFI-AVENTIS (FR) | 2008-02-28 | — | — | US | disclosed |
| US-20080051436-A1 | Use of Acylaminothiazole Derivatives as Therapeutic Agents | SANOFI-AVENTIS (FR) | 2008-02-28 | — | — | US | disclosed |
| EP-1525193-B1 | ACYLAMINOTHIAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2007-12-26 | — | — | EP | disclosed |
| US-7291636-B2 | Acylaminothiazole derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2007-11-06 | — | — | US | disclosed |
| US-7291636-B2 | Acylaminothiazole derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2007-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051436-A1 | Use of Acylaminothiazole Derivatives as Therapeutic Agents | BACE1, BACE2, ATG4A | SYK 2301/4885AURKB 1365/4885INCENP 2482/4885 |
| US-20100190754-A1 | AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF | ARSA, AHR, HRH2 | SYK 775/4885AURKB 2244/4885INCENP 3244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.